December I, 2024

Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.

One new frontier of cancer detection is emerging: metabolomics.

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel therapies.

Lutetium 177 dotatate showed activity and met the PFS end point in patients with surgery- or radiation-refractory grade 2/3 meningioma, per a phase 2 trial presented at ASTRO 2024.

The following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.

The 2024 Nobel Prize in Chemistry highlights AI-driven breakthroughs in computational protein design and structure prediction. Tools like AlphaFold promise faster development of targeted cancer drugs and transformative advances in oncology and medicine.

Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance challenges, and multiple providers, highlighting the need for comprehensive care plans to ensure optimal outcomes.